SCHEMBL9923488

SCHEMBL9923488

Oc1ncc(F)c(OCCc2cnc(Oc3ccc(F)c(C(F)(F)F)c3)c(F)c2)n1

nearest known ligand 0.35

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PLA2G7 Q13093 4/20 0.35
HTR2A P28223 1/20 0.33
SLC6A4 P31645 1/20 0.33
KCNH2 Q12809 1/20 0.33
CDK8 P49336 2/20 0.32
PTPN7 P35236 1/20 0.32
DUSP3 P51452 1/20 0.32
GPR84 Q9NQS5 1/20 0.32
SLC22A12 Q96S37 1/20 0.32
SCN9A Q15858 1/20 0.32
VNN1 O95497 2/20 0.31
RIPK1 Q13546 1/20 0.31
RIPK3 Q9Y572 1/20 0.31
FLT1 P17948 2/20 0.30
FLT4 P35916 2/20 0.30
KDR P35968 2/20 0.30
NR3C2 P08235 1/20 0.30
SMN1; SMN2 Q16637 1/20 0.30
SUCNR1 Q9BXA5 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9923487 0.91 GPR84 (0.42) PLA2G7GPR84SCN9AKDR
SCHEMBL9923491 0.91 HTR2A (0.37) PLA2G7HTR2ASLC6A4KCNH2GPR84
SCHEMBL9905023 0.88 POLB (0.41) PLA2G7HTR2ASLC6A4KCNH2GPR84
SCHEMBL15277237 0.87 PLA2G7 (0.35) PLA2G7HTR2ASLC6A4KCNH2PTPN7
SCHEMBL9900913 0.85 PLA2G7 (0.41) PLA2G7GPR84SCN9AKDR
SCHEMBL9905509 0.83 PLA2G7 (0.36) PLA2G7GPR84VNN1
SCHEMBL9901028 0.81 PLA2G7 (0.38) PLA2G7HTR2ASLC6A4KCNH2CDK8
SCHEMBL9904539 0.81 PLA2G7 (0.35) PLA2G7HTR2ASLC6A4KCNH2CDK8
SCHEMBL9923513 0.81 GPR84 (0.44) PLA2G7GPR84KDR
SCHEMBL9900872 0.81 HTR2A (0.39) PLA2G7HTR2ASLC6A4KCNH2GPR84

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-8859573-B2 Pyrimidinone and pyridinone compounds for use in the treatment of diseases or conditions mediated by Lp-PLA2 GLAXO GROUP LIMITED (GB) 2014-10-14 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
US-20130252986-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-09-26 US disclosed
WO-2012075917-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2012-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130252986-A1 COMPOUNDS LIPG, ENPP2, PLA2G1B PLA2G7 6/4885HTR2A 2268/4885SLC6A4 4549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.